Ftse Mib
34.490,71
0,07%
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
NASDAQ
16.920,79
1,10%
Bitcoin
68.862,64
-0,59%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Hoth Therapeutics Inc (HOTH) Hoth Therapeutics Inc (HOTH) Notizie

HOTH

Hoth Therapeutics (HOTH)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:HOTH
DataOraFonteTitoloSimboloCompagnia
14/05/202422:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOTHHoth Therapeutics Inc
01/05/202414:00PR Newswire (US)Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024NASDAQ:HOTHHoth Therapeutics Inc
27/03/202419:00PR Newswire (US)Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross ProceedsNASDAQ:HOTHHoth Therapeutics Inc
27/03/202413:27PR Newswire (US)Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity TreatmentNASDAQ:HOTHHoth Therapeutics Inc
19/03/202413:21PR Newswire (US)Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZNASDAQ:HOTHHoth Therapeutics Inc
29/02/202414:38PR Newswire (US)Hoth Therapeutics Retains Venable LLP to Expand Its Patent PortfolioNASDAQ:HOTHHoth Therapeutics Inc
26/02/202414:11PR Newswire (US)Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting TherapeuticNASDAQ:HOTHHoth Therapeutics Inc
13/02/202417:45PR Newswire (US)Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024NASDAQ:HOTHHoth Therapeutics Inc
18/01/202414:20PR Newswire (US)Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill PatientsNASDAQ:HOTHHoth Therapeutics Inc
09/01/202421:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
08/01/202423:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOTHHoth Therapeutics Inc
27/12/202314:21PR Newswire (US)Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of MiamiNASDAQ:HOTHHoth Therapeutics Inc
05/12/202314:33PR Newswire (US)Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling StudiesNASDAQ:HOTHHoth Therapeutics Inc
14/11/202314:37PR Newswire (US)Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KITNASDAQ:HOTHHoth Therapeutics Inc
10/11/202314:00PR Newswire (US)Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023NASDAQ:HOTHHoth Therapeutics Inc
05/10/202316:03PR Newswire (US)Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug DiscoveryNASDAQ:HOTHHoth Therapeutics Inc
02/10/202314:33PR Newswire (US)FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer PatientsNASDAQ:HOTHHoth Therapeutics Inc
15/09/202320:38PR Newswire (US)Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesNASDAQ:HOTHHoth Therapeutics Inc
14/09/202323:24Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HOTHHoth Therapeutics Inc
13/09/202319:43PR Newswire (US)Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesNASDAQ:HOTHHoth Therapeutics Inc
13/09/202314:16PR Newswire (US)Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid LeukemiaNASDAQ:HOTHHoth Therapeutics Inc
11/09/202316:04PR Newswire (US)Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer PatientsNASDAQ:HOTHHoth Therapeutics Inc
06/09/202314:12PR Newswire (US)Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexaNASDAQ:HOTHHoth Therapeutics Inc
21/08/202323:00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:HOTHHoth Therapeutics Inc
09/08/202314:13PR Newswire (US)Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's DiseaseNASDAQ:HOTHHoth Therapeutics Inc
25/07/202314:12PR Newswire (US)Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical TrialNASDAQ:HOTHHoth Therapeutics Inc
19/07/202314:02PR Newswire (US)Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer TherapeuticNASDAQ:HOTHHoth Therapeutics Inc
27/06/202322:22Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:HOTHHoth Therapeutics Inc
27/06/202322:21Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:HOTHHoth Therapeutics Inc
14/06/202314:12PR Newswire (US)Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical SiteNASDAQ:HOTHHoth Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:HOTH

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
TIT
Telecom Italia
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TEN
Tenaris
BIT
RACE
Ferrari NV
BIT
SPM
Saipem
BIT
BAMI
Banco BPM
BIT
PRY
Prysmian
BIT
BPE
Bper Banca
BIT
TITR
Telecom Italia
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network